Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

Mesa, R A

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. [electronic resource] - Leukemia Nov 2006 - 2063-4 p. digital

Publication Type: Case Reports; Letter

0887-6924

10.1038/sj.leu.2404398 doi


Acute Disease
Aged, 80 and over
Chromosome Deletion
Chromosomes, Human, Pair 5
Female
Humans
Janus Kinase 2--genetics
Lenalidomide
Leukemia, Myeloid--drug therapy
Myelodysplastic Syndromes--complications
Point Mutation
Thalidomide--analogs & derivatives